Literature DB >> 27155978

Modeling neutralization of Shiga 2 toxin by A-and B-subunit-specific human monoclonal antibodies.

Vladas Skakauskas1, Pranas Katauskis2.   

Abstract

A mathematical model for Shiga 2 toxin neutralization by A-and B-subunit-specific human monoclonal antibodies initially delivered in the extracellular domain is presented, taking into account toxin and antibodies interaction in the extracellular domain, diffusion of toxin, antibodies, and their reaction products toward the cell, the receptor-mediated toxin and complex composed of toxin and antibody to A-subunit internalization from the extracellular into the intracellular medium and excretion of this complex back to the extracellular environment via recycling endosomal carriers. The retrograde transport of the intact toxin to the endoplasmic reticulum and its anterograde movement back to the vicinity of the plasma membrane with its subsequent exocytotic removal to the extracellular space via the secretory vesicle pathway is also taken into account. The model is composed of a set of coupled PDEs. A mathematical model based on a system of ODEs for Shiga 2 toxin neutralization by antibodies in the absence of cell is also studied. Both PDE and ODE systems are solved numerically. Numerical results are illustrated by figures and discussed.

Entities:  

Keywords:  Antibody; Cell receptor; Microtubule transport; Molecular motors; Toxin

Mesh:

Substances:

Year:  2016        PMID: 27155978      PMCID: PMC4942423          DOI: 10.1007/s10867-016-9416-5

Source DB:  PubMed          Journal:  J Biol Phys        ISSN: 0092-0606            Impact factor:   1.365


  26 in total

1.  Models of motor-assisted transport of intracellular particles.

Authors:  D A Smith; R M Simmons
Journal:  Biophys J       Date:  2001-01       Impact factor: 4.033

Review 2.  Transport of protein toxins into cells: pathways used by ricin, cholera toxin and Shiga toxin.

Authors:  Kirsten Sandvig; Bo van Deurs
Journal:  FEBS Lett       Date:  2002-10-02       Impact factor: 4.124

3.  Modeling of toxin-antibody interaction and toxin transport toward the endoplasmic reticulum.

Authors:  Vladas Skakauskas; Pranas Katauskis
Journal:  J Biol Phys       Date:  2015-08-26       Impact factor: 1.365

4.  A model of intracellular transport of particles in an axon.

Authors:  Avner Friedman; Gheorghe Craciun
Journal:  J Math Biol       Date:  2005-07-13       Impact factor: 2.259

5.  Movement of organelles along filaments dissociated from the axoplasm of the squid giant axon.

Authors:  R D Vale; B J Schnapp; T S Reese; M P Sheetz
Journal:  Cell       Date:  1985-02       Impact factor: 41.582

6.  Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins.

Authors:  Y Endo; K Tsurugi; T Yutsudo; Y Takeda; T Ogasawara; K Igarashi
Journal:  Eur J Biochem       Date:  1988-01-15

7.  Human Stx2-specific monoclonal antibodies prevent systemic complications of Escherichia coli O157:H7 infection.

Authors:  Jean Mukherjee; Kerry Chios; Dianne Fishwild; Deborah Hudson; Susan O'Donnell; Stephen M Rich; Arthur Donohue-Rolfe; Saul Tzipori
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

8.  Associations between virulence factors of Shiga toxin-producing Escherichia coli and disease in humans.

Authors:  P Boerlin; S A McEwen; F Boerlin-Petzold; J B Wilson; R P Johnson; C L Gyles
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

9.  Glycolipid binding of purified and recombinant Escherichia coli produced verotoxin in vitro.

Authors:  C A Lingwood; H Law; S Richardson; M Petric; J L Brunton; S De Grandis; M Karmali
Journal:  J Biol Chem       Date:  1987-06-25       Impact factor: 5.157

10.  Kinetic analysis of binding between Shiga toxin and receptor glycolipid Gb3Cer by surface plasmon resonance.

Authors:  H Nakajima; N Kiyokawa; Y U Katagiri; T Taguchi; T Suzuki; T Sekino; K Mimori; T Ebata; M Saito; H Nakao; T Takeda; J Fujimoto
Journal:  J Biol Chem       Date:  2001-09-13       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.